Daniel Eriksson

802 total citations
38 papers, 539 citations indexed

About

Daniel Eriksson is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Internal Medicine. According to data from OpenAlex, Daniel Eriksson has authored 38 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 10 papers in Hematology and 7 papers in Internal Medicine. Recurrent topics in Daniel Eriksson's work include Atrial Fibrillation Management and Outcomes (13 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Daniel Eriksson is often cited by papers focused on Atrial Fibrillation Management and Outcomes (13 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Daniel Eriksson collaborates with scholars based in Germany, Sweden and United States. Daniel Eriksson's co-authors include Thomas J. Bunz, Craig I Coleman, Anna‐Katharina Meinecke, Nitesh Sood, William L. Baker, Reinhold Kreutz, Floortje van Nooten, James Jackson, David Goldsmith and Brandon Martinez and has published in prestigious journals such as Journal of Clinical Investigation, The American Journal of Medicine and European Heart Journal.

In The Last Decade

Daniel Eriksson

35 papers receiving 526 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Eriksson Germany 13 293 163 73 72 67 38 539
Gershon Frisch Canada 4 167 0.6× 83 0.5× 41 0.6× 84 1.2× 228 3.4× 5 429
Kevin Francis United States 8 132 0.5× 48 0.3× 38 0.5× 57 0.8× 23 0.3× 18 327
Mika Skeppholm Sweden 15 584 2.0× 270 1.7× 94 1.3× 101 1.4× 5 0.1× 23 728
Nakarin Sansanayudh Thailand 10 155 0.5× 72 0.4× 64 0.9× 23 0.3× 9 0.1× 32 422
Antonia Sambola Spain 11 436 1.5× 85 0.5× 78 1.1× 87 1.2× 8 0.1× 29 622
Sridhar Kamath United Kingdom 6 301 1.0× 117 0.7× 68 0.9× 34 0.5× 4 0.1× 10 418
B. Imbert France 11 70 0.2× 116 0.7× 50 0.7× 24 0.3× 22 0.3× 38 477
J.-B. Hansen Norway 7 173 0.6× 294 1.8× 95 1.3× 179 2.5× 34 0.5× 10 547
Thomas Kümler Denmark 12 392 1.3× 39 0.2× 63 0.9× 7 0.1× 18 0.3× 37 564
Neil Edward United Kingdom 7 107 0.4× 173 1.1× 19 0.3× 82 1.1× 132 2.0× 9 437

Countries citing papers authored by Daniel Eriksson

Since Specialization
Citations

This map shows the geographic impact of Daniel Eriksson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Eriksson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Eriksson more than expected).

Fields of papers citing papers by Daniel Eriksson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Eriksson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Eriksson. The network helps show where Daniel Eriksson may publish in the future.

Co-authorship network of co-authors of Daniel Eriksson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Eriksson. A scholar is included among the top collaborators of Daniel Eriksson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Eriksson. Daniel Eriksson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cooper, Nichola, Sı́lvia Stanisçuaski Guterres, Koo Wilson, et al.. (2025). The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK. Journal of Market Access & Health Policy. 13(2). 11–11. 1 indexed citations
2.
Wilson, Koo, Francesca Chiodi, Zalmaï Hakimi, et al.. (2025). Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison. Advances in Therapy. 42(5). 2445–2464. 1 indexed citations
3.
4.
5.
6.
Lowe, Gillian, Lone Hvitfeldt Poulsen, Susan Shapiro, et al.. (2023). Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries. Advances in Therapy. 40(9). 3770–3783. 4 indexed citations
7.
Bullement, Ash, et al.. (2021). An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA). Open Access Rheumatology Research and Reviews. Volume 13. 257–266. 2 indexed citations
8.
Hannemann, Nicole, Shan Cao, Daniel Eriksson, et al.. (2019). Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. Journal of Clinical Investigation. 129(7). 2669–2684. 56 indexed citations
9.
Coleman, Craig I, Reinhold Kreutz, Nitesh Sood, et al.. (2019). Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. The American Journal of Medicine. 132(9). 1078–1083. 91 indexed citations
10.
Mueller, S., et al.. (2019). PCV137 ADHERENCE TO ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS OF A MULTI-COUNTRY STUDY. Value in Health. 22. S567–S567. 1 indexed citations
11.
Coleman, Craig I, William L. Baker, Anna‐Katharina Meinecke, et al.. (2019). Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. European Heart Journal - Cardiovascular Pharmacotherapy. 6(3). 159–166. 20 indexed citations
12.
Martinez, Brandon, William L. Baker, Nitesh Sood, et al.. (2018). Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 39(2). 196–203. 17 indexed citations
13.
Martinez, Brandon, Thomas J. Bunz, Daniel Eriksson, et al.. (2018). Effectiveness and Safety of Rivaroxaban vs. Warfarin in Patients with Non-Valvular Atrial Fibrillation and Heart Failure. ESC Heart Failure. 6(1). 10–15. 8 indexed citations
14.
Coleman, Craig I, Alexander G.G. Turpie, Thomas J. Bunz, et al.. (2018). Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. European Heart Journal - Cardiovascular Pharmacotherapy. 5(2). 64–69. 11 indexed citations
15.
Eriksson, Daniel, et al.. (2017). Real-world costs of autosomal dominant polycystic kidney disease in the Nordics. BMC Health Services Research. 17(1). 560–560. 19 indexed citations
16.
Goldsmith, David, et al.. (2016). Real-World, Cross-Sectional, Descriptive Study Of The Quality Of Life Of Patients With Anemia And Chronic Kidney Disease Across Europe. Value in Health. 19(3). A132–A132. 1 indexed citations
17.
Eriksson, Daniel, et al.. (2016). Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrology. 17(1). 97–97. 64 indexed citations
18.
19.
Eriksson, Daniel, et al.. (2015). Autosomal Polycystic Kidney Disease (Adpkd): Costs And Resource Utilisation In The Nordic Countries. Value in Health. 18(7). A513–A513. 2 indexed citations
20.
Jonsson, E, Daniel Eriksson, Kristina Åkesson, et al.. (2015). Swedish osteoporosis care. Archives of Osteoporosis. 10(1). 222–222. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gershon Frisch Breakdown of academic impact, for papers by Kevin Francis Breakdown of academic impact, for papers by Mika Skeppholm Breakdown of academic impact, for papers by Nakarin Sansanayudh Breakdown of academic impact, for papers by Antonia Sambola Breakdown of academic impact, for papers by Sridhar Kamath Breakdown of academic impact, for papers by B. Imbert Breakdown of academic impact, for papers by J.-B. Hansen Breakdown of academic impact, for papers by Thomas Kümler Breakdown of academic impact, for papers by Neil Edward
Rankless by CCL
2026